The Role of B7‐1/B7‐2:CD28/CLTA‐4 Pathways in the Prevention of Anergy, Induction of Productive Immunity and Down‐Regulation of the Immune Response
Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), L M Nadler(Dana-Farber Cancer Institute), John G. Grffiben(Dana-Farber Cancer Institute), Gordon J. Freeman(Harvard University)
Cited by 161
Related Papers
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
|The Journal of Experimental Medicine|2000|5.2k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.1k
ICOS is critical for CD40-mediated antibody class switching
|Nature|2001|644
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
|Frontiers in Immunology|2016|596